Tandem Diabetes Care Inc (TNDM) concluded trading on Thursday at a closing price of $19.98, with 4.75 million shares of worth about $94.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.99% during that period and on May 01, 2025 the price saw a gain of about 18.58%. Currently the company’s common shares owned by public are about 66.26M shares, out of which, 66.01M shares are available for trading.
Stock saw a price change of 13.07% in past 5 days and over the past one month there was a price change of 6.67%. Year-to-date (YTD), TNDM shares are showing a performance of -44.53% which decreased to -46.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.75 but also hit the highest price of $53.69 during that period. The average intraday trading volume for Tandem Diabetes Care Inc shares is 1.71 million. The stock is currently trading 16.01% above its 20-day simple moving average (SMA20), while that difference is up 0.20% for SMA50 and it goes to -39.36% lower than SMA200.
Tandem Diabetes Care Inc (NASDAQ: TNDM) currently have 66.26M outstanding shares and institutions hold larger chunk of about 109.04% of that.
The stock has a current market capitalization of $1.33B and its 3Y-monthly beta is at 1.48. It has posted earnings per share of -$1.47 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 1.80. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNDM, volatility over the week remained 6.54% while standing at 6.79% over the month.
Analysts are in expectations that Tandem Diabetes Care Inc (TNDM) stock would likely to be making an EPS of -0.42 in the current quarter, while forecast for next quarter EPS is -0.26 and it is -0.65 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.57 which is -0.36 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.48 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -29.78% while it is estimated to increase by 66.83% in next year. EPS is likely to grow at an annualized rate of 75.56% for next 5-years, compared to annual growth of -28.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on April 10, 2025 offering a Neutral rating for the stock and assigned a target price of $20 to it. Coverage by Morgan Stanley stated Tandem Diabetes Care Inc (TNDM) stock as an Equal-weight in their note to investors on March 05, 2025, suggesting a price target of $22 for the stock. On March 04, 2025, Citigroup Downgrade their recommendations, while on March 03, 2025, Wells Fargo Downgrade their ratings for the stock with a price target of $22. Stock get a Mkt perform rating from Bernstein on February 28, 2025.
